Allarity Therapeutics FY2023 net loss from operations down 50% to $17.1M; stenoparib complete response in Phase 2

Allarity Therapeutics, Inc.

Net loss from operations $17.1M in 2023 vs $34M in 2022 (down 50%); net loss $11.9M vs $16.1M.
R&D expenses $7.1M and G&A $10.0M both flat year-over-year; no product revenue reported.
Interim CEO Thomas Jensen appointed Dec 2023; former Eli Lilly exec Jeremy Graff named Executive Advisor.
Dec 2023 Phase 2 stenoparib data: 1 complete response, 4 stable disease in evaluable advanced ovarian cancer patients.
Expects interim Phase 2 stenoparib data in Q2 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allarity Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $11.9 million.

Period: the year ended December 31, 2023
Net income: $11.9 million
Result: reported results

Exact text from the filing

Net loss was $11.9 million for 2023, compared to $16.1 million for 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-020882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.